Status | Study |
Active, not recruiting |
Study Name: Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Condition: Hereditary Angioedema Date: 2016-04-08 Interventions: Drug: DX-2930 Rollover subject |
Terminated |
Study Name: Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema Condition: Hereditary Angioedema HAE Date: 2016-01-20 Interventions: Drug: avoralstat Other Name: BCX4161 |
Completed |
Study Name: Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects Condition: Hereditary Angioedema (HAE) Date: 2015-12-21 Interventions: Drug: Recombinant human C1 esterase inhibitor |
Completed |
Study Name: Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE Condition: Hereditary Angioedema Date: 2015-10-23 Interventions: Drug: DX-2930 - 300mg/2wk 300 |
Active, not recruiting |
Study Name: Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Condition: Hereditary Angioedema (HAE) Date: 2015-10-20 Interventions: Drug: C1 esterase inhibitor [human] liquid C1 Esterase Inhibitor [Human] Liquid administered Subcutaneou |
Completed |
Study Name: First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers Condition: Hereditary Angioedema Date: 2015-05-13 Interventions: Drug: BCX7353 Drug: Placebo to match BCX73 |
Active, not recruiting |
Study Name: A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Condition: Hereditary Angioedema Types I and II Date: 2014-12-10 Interventions: Biological: C1-esterase inhibitor |
Completed |
Study Name: 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Condition: Hereditary Angioedema HAE Date: 2014-11-24 Interventions: Drug: BCX4161 Drug: Placebo |
Completed |
Study Name: A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor Condition: Hereditary Angioedema Date: 2014-09-16 Interventions: Biological: Recombinant human C1 inhibitor |
Completed |
Study Name: Study to Determine How BCX4161 is Metabolized and Eliminated by the Body Condition: Hereditary Angioedema Date: 2014-08-14 Interventions: Drug: BCX4161 |